Photonews Logo Photonews logo
  • Home
  • Pakistan
    • Punjab
    • Sindh
    • Khyber Pakhtunkhwa
    • Azad Jammu Kashmir
    • Balochistan
    • Gilgit – Baltistan
  • World
  • Business
  • Entertainment
  • Videos
    Good Fortune trailer
    Videos

    First Trailer for Aziz Ansari’s Good Fortune, Starring Keanu Reeves

    May 29, 2025 2 Min Read
    Last of Us Season 2
    Videos

    ‘The Last of Us’ Season 2 Premieres Date What to Expect From HBO’s Hit Series

    April 13, 2025 2 Min Read
    Disney Snow White box office
    Videos

    Snow White Teaser Drops: Gal Gadot and Rachel Zegler Shine

    February 22, 2025 1 Min Read
  • Sports
  • Technology
  • Offbeat
  • Blog
  • Contact
Reading: Ozempic Breakthrough: Global Trial Shows Major MASH Treatment Gains
PhotoNews Pakistan PhotoNews Pakistan
Font ResizerAa
Search
  • Home
  • Pakistan
    • Punjab
    • Sindh
    • Khyber Pakhtunkhwa
    • Balochistan
    • Azad Jammu Kashmir
    • Gilgit – Baltistan
  • World
  • Business
  • Entertainment
  • Videos
  • Sports
  • Technology
  • Offbeat
  • Blog
  • Contact
Have an existing account? Sign In
Follow US
© 2022 Photonews. All Rights Reserved.
Ozempic ESSENCE Trial
PhotoNews Pakistan > Tech > Ozempic Breakthrough: Global Trial Shows Major MASH Treatment Gains
Tech

Ozempic Breakthrough: Global Trial Shows Major MASH Treatment Gains

Web Desk
By Web Desk Published May 5, 2025 5 Min Read
Share
Ozempic. Photo Credit: Pharmacy Planet.
SHARE

A landmark international clinical trial has revealed that Ozempic (semaglutide), widely used for type 2 diabetes and obesity, significantly reduces liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH), a severe fatty liver disease.

Published in the New England Journal of Medicine, the Phase III ESSENCE trial is the first regulatory-level study to demonstrate a treatment’s potential to halt and reverse MASH-related liver damage, offering hope for millions of affected people worldwide.

Groundbreaking Results from the ESSENCE Trial

The ESSENCE trial, conducted across 253 sites in 37 countries, enrolled over 800 adults with MASH, a progressive condition marked by liver inflammation and scarring that can lead to cirrhosis or liver cancer. Led by Professor Philip Newsome of King’s College London and Professor Arun Sanyal of Virginia Commonwealth University, the study compared weekly 2.4 mg Ozempic injections to a placebo over 72 weeks, alongside lifestyle interventions like diet and exercise counselling.

Results were striking: 62.9% of Ozempic-treated patients achieved reduced liver inflammation, compared to 34.3% on placebo. Additionally, 36.8% showed improved liver fibrosis (scarring reduction) versus 22.4% in the placebo group.

The trial’s diverse cohort, with 75% obese and over 50% with type 2 diabetes, also experienced significant weight loss (averaging 8-10% of body weight), lower liver enzyme levels, and improved metabolic markers like blood sugar control.

The diabetes and weight loss drug semaglutide reversed signs of the liver disease MASH, results of a new clinical trial show.https://t.co/LF0eoC4aUO

— Science News (@ScienceNews) May 4, 2025

However, gastrointestinal side effects, including nausea, diarrhoea, and abdominal discomfort, were more frequent in the Ozempic group, affecting about 30% of participants compared to 15% on placebo. These side effects, typically mild to moderate, align with Ozempic’s known profile as a GLP-1 receptor agonist, which mimics a hormone to regulate appetite and insulin.

MASH and MASLD: A Growing Global Concern

MASH, part of metabolic dysfunction-associated steatotic liver disease (MASLD), affects approximately one in five people in the UK and an estimated 25-30% of adults worldwide, driven by rising obesity and diabetes rates. MASLD ranges from simple fatty liver to MASH, which can progress to life-threatening conditions. In the US, MASH is a leading cause of liver transplants, with no licensed treatments currently available. The ESSENCE trial’s findings position Ozempic as a potential game-changer, addressing an urgent unmet medical need.

Ozempic’s mechanism, which promotes weight loss and reduces liver fat by enhancing insulin sensitivity and suppressing appetite, likely contributes to its efficacy in MASH. The trial’s success builds on earlier studies showing semaglutide’s benefits in non-alcoholic fatty liver disease (NAFLD), MASH’s precursor. Still, ESSENCE is the first to meet regulatory standards for advanced liver disease outcomes.

Future Research and Regulatory Path

The research team plans to monitor 1,200 patients over five years to assess Ozempic’s long-term safety and efficacy, particularly its ability to prevent progression to cirrhosis or liver failure. Novo Nordisk, Ozempic’s manufacturer, is preparing to submit trial data to regulatory bodies like the FDA and EMA, aiming for approval as a MASH treatment by 2026. Experts caution that while promising, Ozempic’s cost (approximately $1,000-$1,500 monthly without insurance) and side effect profile may limit accessibility, necessitating further research into affordable alternatives.

Ozempic’s breakthrough in the Phase III ESSENCE trial, reducing MASH inflammation and fibrosis in 62.9% and 36.8% of patients, respectively, heralds a new era in treating severe fatty liver disease (masld). With MASLD affecting one in five UK residents, this advance offers hope for halting a growing health crisis. As long-term studies and regulatory reviews progress, Ozempic could redefine liver disease management, transforming lives worldwide.

TAGGED:Featured
Share This Article
Facebook Twitter Pinterest Whatsapp Whatsapp LinkedIn Email Copy Link Print
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

Dead Take 2025 psychological horror

Dead Take: Surgent Studios’ Psychological Horror Game Set for 2025 Release

Ayatollah Ali Khamenei Iran Nuclear Talks

Iran’s Khamenei Rejects US Nuclear Deal, Defends Uranium Enrichment

Adolescence

Adolescence Becomes Netflix’s Second Biggest English TV Series

Malir Jail Karachi Prisoner Escape

Sindh Orders Arrest of Malir Jail Constable in Massive Jailbreak Probe

Punjab solar panel guidelines 2025

Punjab Issues Solar Panel Installation Guidelines Amid Net Metering Cuts

Post Archives

More Popular from Photonews

PSX Crash
Business

Pakistan Stock Exchange Soars 600+ Points as Bulls Drive KSE-100 Higher

1 Min Read
Mamta Pathak murder case
World

Indian Chemistry Professor’s Defense Argument Stuns Court

3 Min Read
Drake Diamond certifications
Entertainment

Drake Becomes First Artist with 10 RIAA Diamond Certifications

2 Min Read
Top NewsWorld

U.S. Court Blocks Trump’s Bid to Ban International Students at Harvard

A U.S. court in Boston blocked President Donald Trump’s attempt to prevent Harvard University from enrolling…

May 30, 2025
Gilgit - Baltistan

G&B Traders Block Karakoram Highway in Protest Against FBR’s Trade Policies

On June 1, 2025, traders in Gilgit-Baltistan, supported by political parties, intensified their protest against the…

June 2, 2025
Sports

Usain Bolt Offers to Train IShowSpeed in Exclusive Coaching Session

During a livestream while travelling in Europe for the Champions League, popular YouTuber and streamer IShowSpeed…

May 31, 2025
Pakistan

FIA Files Case Against Ex-NADRA Chief Tariq Malik Over $25M Corruption

The Federal Investigation Agency (FIA) registered a case against former National Database and Registration Authority (NADRA)…

June 4, 2025
PhotoNews Pakistan

Always Stay Up to Date

Subscribe to our newsletter to get our newest articles instantly!

Categories

  • World
  • Pakistan
  • Punjab
  • Sindh
  • Khyber Pakhtunkhwa
  • Balochistan
  • Azad Jammu Kashmir

 

  • Top News
  • Business
  • Entertainment
  • Sports
  • Videos
  • Tech
  • Offbeat
  • Blog

© 2024 Phototnews
All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?